Inoculation of the new crown vaccine can reduce the risk of severe illness and death following infection, but some people have a low immune response to the vaccine even following completing three doses of vaccination, or even unable to produce an immune response, resulting in insufficient antibodies in the body, making prevention and treatment in trouble . A 76-year-old man is suffering from lymphoma and needs to be treated with targeted drugs, but the drugs can affect the ability of the immune system. Although the medical community developed a long-acting antibody combination for people with low immunity, while waiting for the drug to be introduced into Hong Kong, the old man was unfortunately diagnosed with new coronary pneumonia. When he was hospitalized, his condition worsened and he eventually passed away.
At present, regarding 2% of the world’s population has insufficient response to the existing new crown vaccine due to various reasons, and their immunity is relatively low, resulting in severe disease and high mortality following contracting the new crown pneumonia. Dr. Lim Wei-sun, a specialist in infection and infectious diseases, pointed out that blood cancer patients or cancer patients undergoing chemotherapy, patients who have received organ transplants, patients who need dialysis treatment or chronic renal failure, are taking immunosuppressive agents and primary immune Patients with systemic insufficiency belong to those with moderate to severe immune insufficiency. Studies have shown that following infection, it may take many months for them to clear the virus, enter the intensive care unit and have a higher chance of death.
In recent years, the medical field has developed a combination of long-acting new crown antibodies. Once injected, immunity can be obtained immediately. Dr. Lin explained that existing general vaccines need to induce a specific immune response that can destroy pathogens. In contrast, long-acting antibody combinations provide protection through direct injection of antibodies, so that the virus cannot bind, which is “passive immunity”.
Studies have confirmed that long-acting antibody combinations can reduce the risk of severe or death from new coronary pneumonia. In addition to prevention, Japan has also become the first country in the world to approve a new crown antibody combination as a treatment for new coronary pneumonia.
